These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31025500)

  • 21. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy.
    Kiszewski AE; De Villa D; Scheibel I; Ricachnevsky N
    Pediatr Dermatol; 2009; 26(1):105-6. PubMed ID: 19250426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report.
    Cirone KD; Lovegrove FE
    SAGE Open Med Case Rep; 2023; 11():2050313X231160937. PubMed ID: 36968989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.
    Smirnova LM; Vertieva EY; Olisova OY; Anpilogova EM
    Biologics; 2019; 13():83-87. PubMed ID: 31190732
    [No Abstract]   [Full Text] [Related]  

  • 26. Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.
    Georgakopoulos JR; Ighani A; Yeung J
    J Cutan Med Surg; 2017; 21(5):452-456. PubMed ID: 28535721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topically administered fluorouracil in acrodermatitis continua of Hallopeau.
    Tsuji T; Nishimura M
    Arch Dermatol; 1991 Jan; 127(1):27-8. PubMed ID: 1986705
    [No Abstract]   [Full Text] [Related]  

  • 28. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
    Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
    J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.
    Adışen E; Özer İ; Temel B; Gürer MA
    Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28139054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau.
    Weisshaar E; Diepgen TL
    J Dtsch Dermatol Ges; 2007 Jun; 5(6):489-92. PubMed ID: 17537042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Off-label studies on apremilast in dermatology: a review.
    Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K
    J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262
    [No Abstract]   [Full Text] [Related]  

  • 38. Apremilast for the treatment of psoriatic arthritis.
    Varada S; Tintle SJ; Gottlieb AB
    Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit.
    Lanna C; Cesaroni GM; Mazzilli S; Vollono L; Gaziano R; Marino D; Bianchi L; Campione E
    J Dermatolog Treat; 2022 Mar; 33(2):1097-1101. PubMed ID: 32715817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.